Liposomal encapsulated doxorubicin (Caelyx) in the treatment of relapsed aggressive non-Hodgkin's lymphoma: A phase II study

Leukemia and Lymphoma

Volumn 47, Issue 7, 2006, Pages 1327-1332

  Macpherson, N ^a   Belch, A ^b   Taylor, M ^a   Sutherland, J ^a   Czaykowski, P ^c   Connors, J ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c Manitoba Clinic   (Canada)

Author keywords

Caelyx; Liposomal encapsulated doxorubicin; Phase II trial; Relapsed non Hodgkin's lymphoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHLORAMBUCIL; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLAVOPIRIDOL; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD CELL COUNT; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG TOLERABILITY; ENCAPSULATION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HUMAN; LARGE CELL LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33747693088     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500519311     Document Type: Article

References (18)

1. Fisher, R and Gaynor, E and Dahlberg, S and Oken, M and Grogan, T and Mize, E and (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 328, pp. 1002-1006.
2. Gabizon, A and Lyass, O and Berry, G and Wildgust, M. (2004) Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest, 22, pp. 663-669.
3. Cheson, B and Horning, S and Coiffier, B and Shipp, M and Fisher, R and Connors, J and (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, pp. 1244.
4. Papahadjopoulos, D and Allen, T and Gabizon, A and Mayhew, E and Matthay, K and Huang, S and (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA, 88, pp. 11460-11464.
5. Martin, F and Gabizon, A. (1992) Human pharmacokinetics of stealth liposomes containing doxorubicin. J Cell Biochem, 16E, pp. 98.
6. North, D. (1993) Tumour localization and safety of DOXIL (liposomal doxorubicin) in AIDS patients with Kaposi's sarcoma. Proc Am Soc Clin Oncol, 12, pp. 51.
7. Bender, R and Anderson, T and Fisher, R and Young, R. (1978) Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin lymphoma. Am J Hematol, 5, pp. 203-209.
8. Dombernowsky, P and Nissen, N and Larsen, V. (1972) Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4′-demethyl-9-(4,6-O-2-thenylidene-D-glucopyranoside) (NSC- 122819), in patients with malignant lymphomas and solid tumors. Cancer Chemother Rep, 56, pp. 71-82.
9. Gams, R and Bryan, S and Dukart, G and Weiss, A and Case, D and Jones, S and (1985) Mitoxantrone in malignant lymphoma. Invest New Drugs, 3, pp. 219-222.
10. Preti, A and Cabanillas, F.(1997) Management of recurrent or refractory lymphomas. In The Non-Hodgkin's Lymphomas. (pp. 415-722). London: Oxford University Press.
11. Tulpule, A and Espina, B and Byron, M and Berman, N and Buchanan, L and Boswell, W and (2001) Liposomal doxorubicin (TLC-D99) in combination with cyclophosphamide, vincristine, and prednisone is active in newly diagnosed aggressive non-Hodgkin's lymphoma.Blood, 98, pp. 346a.
12. Chanan-Khan, A and Islam, T and Bernstein, S and Bernstein, Z and Alam, A and McCarthy, P and (2001) CDOP (Cyclophosphamide, Doxil, Vincristine, Prednisone) as a front-line regimen for elderly patients with intermediate grade non-Hodgkin's lymphoma. Blood. 98(11 part 2):239b
13. Di Bella, N and Khan, M and Dakhil, S and Logie, K and Marsland, T and Weinstein, R and (2003) Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin's lymphoma: A phase II multicenter study. Clin Lymphoma, 3, pp. 235-240.
14. Swain, S and Whaley, F and Ewer, M. (2003) Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer, 97, pp. 2869-2879.
15. Hortobagyi, G. (1997) Anthracyclines in the treatment of cancer. An overview Drugs, 54(Suppl 4), pp. 1-7.
16. Pai, V and Nahata, M. (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf, 22, pp. 263-302.
17. Berry, G and Billingham, M and Alderman, E and Richardson, P and Torti, F and Lum, B and (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol, 9, pp. 711-716.
18. 2. Ann Oncol, 11, pp. 1029-1033.